Determination of liraglutide in rat plasma by a selective liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetics study

Su, Dong; Gu, Yuan; Wei, Guangli; Si, Duanyun; Liu, Changxiao

doi:10.1016/j.jchromb.2018.05.020

Cited by 22 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a single method for simultaneously determining liraglutide and insulin degludec in samples has not been established. Dong, Gu, Wei, Si, and Liu (2018) developed and validated a sensitive LC–tandem mass spectrometry (LC–MS/MS) method for quantifying the concentration of liraglutide in rat plasma with a lower limit of quantification (LLOQ) of 0.5 ng/mL. In this method, only 100 μL precipitant was added to 50 μL plasma, and protein precipitation was incomplete.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography–tandem mass spectrometry method and its application

Zhai

Dong

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

A simple, fast and high‐throughput LC–tandem mass spectrometry method was developed and validated to simultaneously measure liraglutide and insulin degludec in rat plasma. After protein precipitation, plasma samples were subjected to gradient elution using an InertSustain Bio C18 column with 1000/20/1 water/acetonitrile/formic acid (v/v/v) and 1000/1 acetonitrile/formic acid (v/v) as the mobile phase. The method was validated from 1.00 to 500 ng/mL of liraglutide and insulin degludec. Further, the extraction recovery from the plasma was 41.8%–49.2% for liraglutide and 56.5%–69.7% for insulin degludec. Intra‐ and inter‐day precision of liraglutide was 3.5%–9.4% and 8.4%–9.8%, respectively, whereas its accuracy was between −12.6% and −1.3%. Intra‐ and inter‐day precision of insulin degludec was 5.2%–13.6% and 11.8%–19.1%, respectively, showing an accuracy between −3.0% and 9.9%. As a result, the method was successfully applied to a pharmacokinetics study of liraglutide and insulin degludec following a single‐dose subcutaneous administration to rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography–tandem mass spectrometry method and its application

Zhai

Dong

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Compared with exenatide, the absorption of AWRK6 was slower and the retention time in the body was longer [ 14 ]. Whereas the absorption and clearance of liraglutide are much slower than those of AWRK6 and exenatide [ 15 ]. In follow-up studies, the pharmacokinetic properties of AWRK6 will be explored for enhancement through further modification and chemical modification, as well as pharmaceutical strategies such as nanosizing.…”

Section: Discussionmentioning

confidence: 99%

Determination of the Peptide AWRK6 in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and Its Application to Pharmacokinetics

et al. 2021

View full text Add to dashboard Cite

AWRK6 was a synthesized peptide developed based on the natural occurring peptide dybowskin-2CDYa, which was discovered in frog skin in our previous study. Here, a quantitative determination method for AWRK6 analysis in rat plasma by using liquid chromatography-tandem mass spectrometry (LC-MS/MS) was established and validated following U.S. FDA guidelines. A combination of plasma precipitation and liquid–liquid extraction was applied for the extraction. For pharmacokinetics study, the rats were administrated with AWRK6 via intraperitoneal and intravenous injection. The prepared plasma samples were separated on an ODS column and analyzed by tandem MS using precursor-to-product ion pairs of m/z: 533.4→84.2 for AWRK6 and m/z: 401.9→101.1 for internal standard Polymyxin B sulfate in multiple reaction monitoring mode. AWRK6 concentrations in rat plasma peaked at about 1.2 h after intraperitoneal injections at 2.35, 4.7 and 9.4 mg/kg bodyweight. The terminal half-life was around 2.8 h. The absolute bioavailability of AWRK6 was 50% after 3 doses via injection, and the apparent volume of distribution was 4.884 ± 1.736 L. The obtained determination method and pharmacokinetics profiles of AWRK6 provides a basis for further development, and forms a benchmark reference for peptide quantification.

show abstract

“…Biological samples (plasma, tissue homogenates, urine, and fecal homogenates) were thawed at room temperature and vortexed for 10 s, followed by protein precipitation. Take 50 μl of biological sample, add 50 μl of verapamil working solution and 150 μl of precipitant (methanol: acetonitrile, 3:7), vortex for 2 min, centrifuge at 12000 rpm for 10 min at 4°C, and take 100 μl of supernatant to put in the injection vial, 1 μl was quantitatively detected by LC-MS/MS ( Dong et al, 2018 ). The calibration curve and quality control samples were processed as above.…”

Section: Methodsmentioning

confidence: 99%

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats

et al. 2022

View full text Add to dashboard Cite

Purpose: The “radiotherapy-pharmacokinetic” (“RT-PK”) phenomenon refers to the fact that radiation can significantly alter the pharmacokinetic behavior of a drug. At present, it is not clear whether there is an “RT-PK” phenomenon that can affect apatinib during concurrent chemoradiotherapy. In this study, we used a rat irradiation model to study the effects of X-ray radiation on absorption, tissue distribution, and excretion of apatinib.Method: Healthy Sprague-Dawley (SD) rats were randomly divided into control and radiation groups. The radiation group was given an appropriate dose of abdominal X-ray radiation, while the control group was not given irradiation. After 24 h of recovery, both groups were given apatinib solution 45 mg/kg by gavage. A quantitative LC-MS/MS method was developed to determine the concentration of apatinib in the rats, so as to compare the differences between the control and radiation groups and thus investigate the modulating effect of radiation on the pharmacokinetics of apatinib in rats.Results: After abdominal X-ray irradiation, the area under the curve (AUC0-t) of apatinib in rat plasma decreased by 33.8% and 76.3% at 0.5 and 2 Gy, respectively. Clearance (CL) and volume of distribution (Vd) increased and were positively correlated with radiation dose. X-ray radiation significantly reduced the concentration of apatinib in the liver and small intestine, and there was no tissue accumulation. In excretion studies, we found that X-ray radiation reduced the cumulative excretion of apatinib in feces and urine by 11.24% and 86.17%, respectively.Conclusion: Abdominal X-ray radiation decreased plasma exposure, tissue distribution, and excretion of apatinib in rats, suggesting that the RT-PK phenomenon affects apatinib. We speculate that this RT-PK phenomenon is closely related to changes in metabolic enzymes in vivo. In clinical practice, when apatinib is combined with radiotherapy, attention should be paid to adjusting the dose of apatinib and optimizing the treatment plan to alleviate the adverse effects of this RT-PK phenomenon.

show abstract

Determination of liraglutide in rat plasma by a selective liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetics study

Cited by 22 publications

References 28 publications

Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography–tandem mass spectrometry method and its application

Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography–tandem mass spectrometry method and its application

Determination of the Peptide AWRK6 in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and Its Application to Pharmacokinetics

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats

Contact Info

Product

Resources

About